Skip to main content

Table 2 Summary of global resting and post-acetazolamide CBF in Fabry disease compared to controls together with the mean resting and post-acetazolamide global CBF changes in the ERT Fabry and placebo groups following the double-blind, placebo-controlled randomized trial. All values are means ± standard deviation.

From: Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease

Global Cerebral Blood Flow [ml/min/100 g tissue]

Fabry Patients

Control Subjects

P value

Rest

42.0 ± 4.9, n = 26

39.2 ± 4.8, n = 10

0.136

Post-acetazolamide 20 minute time point

57.5 ± 8.9, n = 26

57.9 ± 7.9, n = 9

0.969

Post-acetazolamide 30 minute time point

56.9 ± 7.9, n = 26

54.2 ± 8.6, n = 10

0.406

Cerebral Blood Flow change Post-ERT or Placebo

Enzyme Replacement Group

Placebo Group

P value

Resting Cerebral Blood Flow

-3.5 ± 4.6, n = 14

1.3 ± 5.1, n = 11

0.026

Post-acetazolamide 20 minute time point

-3.9 ± 7.9, n = 13

0.5 ± 10.8, n = 9

0.314

Post-acetazolamide 30 minutes time point

-7.0 ± 5.5, n = 13

1.1 ± 9.2, n = 9

0.036